Verity Asset Management Inc. Acquires 2,287 Shares of Halozyme Therapeutics, Inc. $HALO

Verity Asset Management Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,410 shares of the biopharmaceutical company’s stock after acquiring an additional 2,287 shares during the quarter. Halozyme Therapeutics accounts for approximately 1.1% of Verity Asset Management Inc.’s investment portfolio, making the stock its 21st biggest holding. Verity Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $2,310,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.0% in the first quarter. Principal Financial Group Inc. now owns 380,021 shares of the biopharmaceutical company’s stock valued at $24,249,000 after purchasing an additional 3,826 shares in the last quarter. OneDigital Investment Advisors LLC raised its position in Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 175 shares during the last quarter. GF Fund Management CO. LTD. raised its position in Halozyme Therapeutics by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,258 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 587 shares during the last quarter. Brookstone Capital Management lifted its stake in Halozyme Therapeutics by 1.7% during the 1st quarter. Brookstone Capital Management now owns 61,601 shares of the biopharmaceutical company’s stock valued at $3,931,000 after acquiring an additional 1,014 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics during the 1st quarter worth $125,000. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, October 21st. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Finally, Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Four analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $73.11.

Halozyme Therapeutics Stock Up 0.9%

HALO opened at $65.19 on Monday. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50. The company’s 50-day moving average price is $71.16 and its two-hundred day moving average price is $62.56. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 0.35 and a beta of 1.16. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter last year, the business posted $0.91 EPS. Halozyme Therapeutics’s quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Nicole Labrosse sold 2,227 shares of Halozyme Therapeutics stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. This trade represents a 9.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the sale, the director owned 44,952 shares in the company, valued at $3,382,188.48. This represents a 4.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 108,227 shares of company stock valued at $7,779,595 over the last ninety days. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.